New trial aims to boost COVID-19 protection for vulnerable patients
Disease control
Recruiting now
This study is testing whether giving a longer course of the antiviral Paxlovid (10 days instead of 5) or combining it with another antiviral (remdesivir) helps immunocompromised people clear COVID-19 faster. About 256 participants with mild to moderate COVID-19 and weakened immun…
Phase: PHASE2 • Sponsor: Calmy Alexandra • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC